Howard Fingert

Howard Fingert's work experience begins with their role as Vice President of Medical Oncology Research and Development at ONO PHARMA USA, INC., starting in 2022. In this position, Fingert is dedicated to serving cancer patients and their families by developing new options for treatment and prevention.

Prior to their current role, Fingert served as the Senior Managing Director of Howard J Fingert, MD Consulting, LLC from 2019 to 2022. In this role, they optimized integration among various organizations to enhance the quality and efficiency of clinical research protocols. Howard also focused on training clinical research professionals and exploring licensing opportunities and public-private partnerships.

From 2016 to 2019, Fingert served as the Industry Representative to the National Cancer Inst.'s Clinical Trials And Translational Research Advisory Committee (CTAC). During their time in this role, they collaborated with FDA staff and statisticians to develop consensus on the use of external clinical data in protocol designs and regulatory decision-making.

Fingert also held leadership positions at Alkermes Pharmaceuticals as the Vice President of Oncology from 2018 to 2019 and at Takeda Pharmaceuticals as the Senior Medical Director from 2008 to 2018. At Takeda, they played a key role in managing protocol designs and analyses for regulatory approval and global adoption. Howard also led the development of the aurora kinase inhibitor Alisertib in multiple heme and solid tumor indications.

Additionally, Fingert held roles at Pfizer from 2002 to 2008, including Senior Medical Director and Oncology Therapeutic Area Head. In these positions, they focused on developing risk mitigation strategies and operational efficiencies for oncology products. Howard also played a significant role in the Pfizer-Pharmacia acquisition and authored the first oncology-specific template for integrated summaries used in regulatory submissions.

Fingert's work experience also includes roles as an Expert Working Group member for the International Conference on Harmonization's Modernization Initiative from 2017 to 2018 and as the Industry Representative to the FDA Oncology Drugs Advisory Committee from 2013 to 2016.

Throughout their career, Fingert has demonstrated a commitment to advancing clinical development practices, promoting collaboration among stakeholders, and advocating for patient-centered research and innovation in oncology.

Howard Fingert has a strong educational background in the field of medicine, specifically in oncology and hematology. Howard attended Harvard Medical School, although the specific dates of their enrollment are not provided. Prior to that, they pursued a pre-medical and religious studies degree at Brandeis University from 1968 to 1973, earning both a Bachelor of Arts (BA) and a Master of Arts (MA) degree. In addition to their formal education, Fingert has obtained certifications in Good Clinical Practices training from the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, which they completed in May 2020. Howard also holds certifications in Medical Oncology and Hematology from the American Board of Internal Medicine, although the specific dates of these certifications are not given.